J&J’s anti-BCMA CAR-T pads its case ahead of speedy review and Bristol Myers showdown
Just days after moving their multiple myeloma CAR-T into the FDA’s fast lane, Johnson & Johnson and Legend Biotech are unveiling new data to pad its case. The treatment shrank tumors in 98% of very sick patients with multiple myeloma and eliminated them in 80% of patients.